3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gastrointestinal
1
Breast
1
Conditions
Solid Tumors
2
Neoplasms
2
Liposarcoma
2
Biliary Tract Neoplasms
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Tertiary Lymphoid Structures
1
Solid Tumours
1
Sarcoma
1
Pancreatic Neoplasms
1
Lung Neoplasms
1
Histiocytoma, Malignant Fibrous
1
Glioblastoma
1
Dermatofibrosarcoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Doxorubicin
141
Ifosfamide
85
Radiotherapy
80
Cyclophosphamide
72
Gemcitabine
63
Filgrastim
54
pembrolizumab
43
pazopanib
39
Etoposide
39
Docetaxel
39
Vincristine
37
Cisplatin
35
Trabectedin
32
Nivolumab
32
Irinotecan
26
Magnetic Resonance Spectroscopy
25
Carboplatin
25
Temozolomide
23
Ipilimumab
22
Bevacizumab
20
Radiation
19
Granulocyte Colony-Stimulating Factor
18
Surgical Procedures, Operative
17
Sirolimus
17
Mesna
17
Melphalan
17
Dactinomycin
17
Biopsy
17
eribulin
16
Specimen Handling
16
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Sarcoma
×
brigimadlin
×
Clear all
NCT06084689
2025-09-02
EMPIRE
Institut Bergonié
Phase 2
Withdrawn